Want to see SION full AI Analyst Report?
Sionna Therapeutics, Inc. (SION) Stock Statistics & Valuation Metrics
Total Valuation
Sionna Therapeutics, Inc. has a market cap or net worth of $174.97M. The enterprise value is $1.78B.
- Market Cap
- $174.97M
- Enterprise Value
- $1.78B
Share Statistics
Sionna Therapeutics, Inc. has 45,212,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,212,400
- Owned by Insiders
- 48.59%
- Owned by Institutions
- 15.93%
Financial Efficiency
Sionna Therapeutics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -28.20%.
- Return on Equity (ROE)
- -0.25
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -28.20%
- Return on Capital Employed (ROCE)
- -0.28
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.28M
- Employee Count
- 59
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Sionna Therapeutics, Inc. is -1.78. Sionna Therapeutics, Inc.’s PEG ratio is 0.07.
- PE Ratio
- -1.78
- PS Ratio
- 0.00
- PB Ratio
- 0.66
- Price to FCF
- -1.78
- Price to Operating Cash Flow
- -1.79
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Sionna Therapeutics, Inc. had revenue of 0 and earned -75.27M in profits. Earnings per share was -1.88.
- Revenue
- 0
- Gross Profit
- -647.00K
- Operating Income
- -88.98M
- Pretax Income
- -75.27M
- Net Income
- -75.27M
- EBITDA
- -74.62M
- Earnings Per Share (EPS)
- -1.88
Cash Flow
In the last 12 months, operating cash flow was -97.76M and capital expenditures -291,000, giving a free cash flow of -98.05M billion.
- Operating Cash Flow
- -97.76M
- Free Cash Flow
- -98.05M
- Free Cash Flow per Share
- -2.17
Dividends & Yields
Sionna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -56.11%
- Earnings Yield
- -55.73%
Stock Price Statistics
- Beta
- 1.31
- 52-Week Price Change
- -89.82%
- 50-Day Moving Average
- 5.48
- 200-Day Moving Average
- 29.96
- Relative Strength Index (RSI)
- 31.21
- Average Volume (3m)
- 2.30M
Important Dates
Sionna Therapeutics, Inc. upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Sionna Therapeutics, Inc. as a current ratio of 20.61, with Debt / Equity ratio of 2.83%
- Current Ratio
- 20.61
- Quick Ratio
- 20.61
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.67
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Sionna Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Sionna Therapeutics, Inc. EV to EBITDA ratio is -1.28, with an EV/FCF ratio of -1.22.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.28
- EV to Free Cash Flow
- -1.22
- EV to Operating Cash Flow
- -1.22
Balance Sheet
Sionna Therapeutics, Inc. has $211.03M in cash and marketable securities with $8.07M in debt, giving a net cash position of $202.96M billion.
- Cash & Marketable Securities
- $211.03M
- Total Debt
- $8.07M
- Net Cash
- $202.96M
- Net Cash Per Share
- $4.49
- Tangible Book Value Per Share
- $5.89
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Sionna Therapeutics, Inc. is $15.33, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $15.33
- Price Target Upside
- 296.21% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -26.18%
Scores
- Smart Score
- 3
- AI Score
- 43
